ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 ...

Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.The safety pro ...

Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo ...